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Background: Cross-sectional studies have shown associations between arsenic exposure and
prevalence of high blood pressure; however, studies examining the relationship of arsenic exposure
with longitudinal changes in blood pressure are lacking.
Method: We evaluated associations of arsenic exposure in relation to longitudinal change in blood
pressure in 10,853 participants in the Health Effects of Arsenic Longitudinal Study (HEALS).
Arsenic was measured in well water and in urine samples at baseline and in urine samples every
2 years after baseline. Mixed-effect models were used to estimate the association of baseline well
and urinary creatinine-adjusted arsenic with annual change in blood pressure during follow-up
(median, 6.7 years).
Result: In the HEALS population, the median water arsenic concentration at baseline was 62 μg/L.
Individuals in the highest quartile of baseline water arsenic or urinary creatinine-adjusted arsenic
had a greater annual increase in systolic blood pressure compared with those in the reference
group (β = 0.48 mmHg/year; 95% CI: 0.35, 0.61, and β = 0.43 mmHg/year; 95% CI: 0.29, 0.56
for water arsenic and urinary creatinine-adjusted arsenic, respectively) in fully adjusted models.
Likewise, individuals in the highest quartile of baseline arsenic exposure had a greater annual
increase in diastolic blood pressure for water arsenic and urinary creatinine-adjusted arsenic,
(β = 0.39 mmHg/year; 95% CI: 0.30, 0.49, and β = 0.45 mmHg/year; 95% CI: 0.36, 0.55,
respectively) compared with those in the lowest quartile.
Conclusion: Our findings suggest that long-term arsenic exposure may accelerate age-related
increases in blood pressure. These findings may help explain associations between arsenic exposure
and cardiovascular disease.
C itation : Jiang J, Liu M, Parvez F, Wang B, Wu F, Eunus M, Bangalore S, Newman JD,
Ahmed A, Islam T, Rakibuz-Zaman M, Hasan R, Sarwar G, Levy D, Slavkovich V, Argos M,
Scannell Bryan M, Farzan SF, Hayes RB, Graziano JH, Ahsan H, Chen Y. 2015. Association
between arsenic exposure from drinking water and longitudinal change in blood pressure
among HEALS cohort participants. Environ Health Perspect 123:806–812; http://dx.doi.
org/10.1289/ehp.1409004

Introduction
There is a strong and direct relationship
between high blood pressure (BP) and cardiovascular disease (CVD) mortality (Lewington
et al. 2002). High BP remains prevalent in
the United States and internationally among
adults over the age of 35 years (Chobanian
et al. 2003; Frohlich 1997). Rapid increases
in the prevalence of high BP in low-income
countries (Gupta and Gupta 2009; Ibrahim
and Damasceno 2012; Lawes et al. 2003;
Redon et al. 2011) has likely contributed to
the rising epidemic of CVD in these populations (Ibrahim and Damasceno 2012). In
recent decades, there has been growing awareness of the potential importance of environmental factors such as mercury (Houston
2011), lead (Navas-Acien et al. 2007),
cadmium (Eum et al. 2008), and arsenic
(Abhyankar et al. 2012) in the development
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of high BP. The identification and mitigation of environmental exposures associated
with high BP may help reduce CVD risk
(Abhyankar et al. 2012).
Previous studies have indicated associa
tions between exposure to inorganic arsenic
and the development of vascular diseases,
including high BP, peripheral vascular diseases,
and ischemic heart disease (Abhyankar et al.
2012; Chen CJ et al. 1996; Chen Y et al.
2007a; Tseng et al. 1996). A systematic
review examining 11 cross-sectional studies
on arsenic exposure and the prevalence of
high BP (Abhyankar et al. 2012) found
that 10 of the 11 studies reported a positive
association, whereas only one study indicated
no association. The review included 8 studies
with arsenic levels of moderate to high (average
≥ 50 μg/L), and 3 studies with relatively low
arsenic levels (average < 50 μg/L). However,
volume

prospective cohort studies that can better
characterize the association between arsenic
and high BP are lacking. Longitudinal studies
with repeated measurements of BP, which
provide a powerful tool to evaluate health
outcomes that change over time, are needed
to assess whether arsenic is associated with
increasing BP over time.
It is estimated that millions of Americans
are exposed to drinking water with arsenic
concentrations exceeding the World Health
Organization (WHO) standard (10 μg/L)
(U.S. Environmental Protection Agency
2000). In Bangladesh, where the majority
of the population relies on groundwater and
arsenic contamination of wells is widespread,
> 50 million people have been chronically
exposed (British Geological Survey 2007).
In 2000, we established the Health Effects
of Arsenic Longitudinal Study (HEALS), a
large prospective cohort study of 11,746 individuals in Araihazar, Bangladesh, to assess the
health effects of arsenic exposure. In crosssectional analyses using participants’ baseline
data, we previously reported a positive association between baseline arsenic exposure,
measured either in urine or drinking water
samples, and BP (Chen Y et al. 2007a). To
characterize the rate of BP changes related
to arsenic exposure, we assessed the association of baseline arsenic exposure (measured
both in water and urine) with longitudinal
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changes in BP among 10,853 participants
in Bangladesh who had well water arsenic
concentrations ranging from 0.1 to 864 μg/L
(median = 62 μg/L).

Materials and Methods
Study population. HEALS is an ongoing
prospective cohort study in Araihazar,
Bangladesh. The principle aim of HEALS
is to investigate the health effects of arsenic
in drinking water. A detailed description
of the cohort has been presented elsewhere
(Ahsan et al. 2006). Briefly, before recruitment, water samples were collected for a set
of 5,966 continuous wells in a well-defined
geographic area of 25 km 2 in Araihazar.
Between October 2000 and May 2002,
11,746 men and women 18–75 years of age
were recruited who met the following criteria:
a) married male or female (to reduce loss to
follow-up), b) resident of the study area for at
least 5 years, and c) primarily used drinking
water from 1 of the 5,966 study wells for at
least 3 years (Ahsan et al. 2006), leading to
a response rate of 97.5% (original cohort).
HEALS was expanded to include an additional
8,287 participants in 2007–2008 (expansion
cohort) following the same methodologies
(Wu et al. 2011). The present study focused
on the original cohort because these individuals were followed for a longer period of
time (median, 6.7 years; range, 0.9–8.3 years).
Baseline interviews were conducted to gather
information regarding history of well water
use, demographics, and lifestyle characteristics.
The cohort is being actively followed, with
follow-up assessments conducted roughly every
2 years. The current analysis included data
from the first (September 2002–May 2004),
second (September 2004–May 2006), and
third (June 2007–March 2009) follow-ups, at
which time a physical examination, collection
of urine samples, and a structured interview
were conducted using the same procedures as
those used in the baseline interview. Informed
consent was obtained from study participants,
and study procedures were approved by the
ethics committee of the Bangladesh Medical
Research Council and the institutional review
boards of Columbia University and the
University of Chicago.
For the present study, we excluded individuals who died before the first follow-up
(n = 107), those taking hypertension treatment at baseline (n = 126), those without
systolic BP (SBP) or diastolic BP (DBP)
measurements at baseline (n = 380), and individuals for whom no measurements of SBP
or DBP were recorded during the follow-up
(n = 406). The final study population was
10,853. The distributions of demographic
and lifestyle factors between the overall population and the study population were very
similar (see Supplemental Material, Table S1).
Environmental Health Perspectives •
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Measurements of arsenic exposure. In
rural Bangladesh, the majority of the population uses a single hand-pumped tube well
for their primary source of drinking water.
There is no municipal water treatment. Water
samples from 5,966 tube wells were collected
in 50‑mL acid-washed bottles after pumping
each well for 5 min. Samples were immediately acidified using 1% HCl until December
2003, after which samples were acidified at
Columbia University, normally several months
after collection, because delayed acidification
does not affect measurement results (van Geen
et al. 2007). Total arsenic concentration was
first determined by graphite furnace atomic
absorption spectrometry (GFAA), with a
detection limit of 5 μg/L. If water samples
were found to have arsenic concentrations at
or below the detection limit of GFAA, they
were then analyzed by high-resolution inductively coupled plasma mass spectrometry (HR
ICPMS), with a detection limit of < 0.1 μg/L
(Chen Y et al. 2007b). The long-term reproducibility determined from consistency standards included with each run is relatively stable
over time (Cheng et al. 2004, 2005; van Geen
et al. 2005).
Spot urine samples were collected in
50‑mL acid-washed tubes from 95.6, 94.5,
91.6, and 89.9% of the cohort participants
at baseline and at the first, second, and third
follow-up visits, respectively. Total arsenic
concentration was measured by GFAA spectrometry using a PerkinElmer (Waltham,
MA) AAnalyst 600 graphite furnace system
with a detection limit of 2 μg/L, as previously described (Nixon et al. 1991). Urinary
creatinine was analyzed using a method
based on the Jaffe reaction for adjustment
of urinary total arsenic concentration (Slot
1965). The median of creatinine concentration at baseline was 52.3 mg/dL (range,
2.8–376.0) for men and 41.5 mg/dL (range,
1.3–303.1) for women.
Given that drinking water was the main
source of arsenic exposure in the population (see Supplemental Material, “Details
on arsenic exposure in the population”) and
urinary creatinine-adjusted arsenic can reflect
internal dose of exposure (Marchiset-Ferlay
et al. 2012), we used both as indicators for
arsenic exposure. At baseline, in order to help
improve the health of the community and
reduce their risks from arsenic exposure, an
arsenic mitigation program was implemented
to promote switching to wells with relatively
lower water arsenic concentration (< 50 μg/L)
(Chen Y et al. 2007b). At the first follow-up,
a total of 58% of the 6,512 participants who
consumed well water with arsenic concentrations ≥ 50 μg/L at baseline had switched to
nearby wells. However, among those individuals that switched wells, only 27% participants had switched to wells with lower arsenic
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concentrations (i.e., < 50 μg/L) (Chen Y
et al. 2007b). We used urinary creatinineadjusted arsenic assessed at follow-up visits to
track the change in exposure during followups (Marchiset-Ferlay et al. 2012). Because
arsenic level remained similar in the majority
of the participants (see Supplemental Material,
“Details of arsenic exposure in the population”), the impact of visit-to-visit change of
urinary creatinine-adjusted arsenic on BP
change was considered short-term compared
with urinary creatinine-adjusted arsenic at
baseline, which reflected exposure from the
baseline wells that participants had used for an
average of 8.6 (median, 7; range, 3–50) years
prior to baseline (Chen Y et al. 2010, 2011,
2013a, 2013b), and thus visit-to-visit change
of urinary creatinine-adjusted arsenic was not
considered as the main exposure of interest.
BP measurements. BP was measured
at baseline and at each follow-up by trained
clinicians using an automatic sphygmomanometer (HEM 712-C; Omron Healthcare
GmbH, Hamburg, Germany), which has
been validated to have 85% of readings falling
within 10 mmHg (O’Brien et al. 2001).
Measurements were taken with participants in
a seated position after 5 min of rest, with the
cuff around the upper left arm, in accordance
with recommended guidelines (Pickering et al.
2005). Two BP measurements were taken at
follow-ups, and we used the arithmetic mean
of two for the analyses. The reliability of the
BP measurement was high, with all intraclass
correlation coefficients between 0.92 and 0.94
at a given visit (Chen Y et al. 2007a).
The participation rate for the first, second,
and third follow-ups, respectively, were 96.9,
93.6, and 92.2% of the cohort participants at
baseline. Information on medication use was
collected at baseline and during follow-ups.
Study participants were asked about all medicines they were taking regularly, and were
asked to show the medications or prescriptions to the interviewers. Medications were
standardized to generic names and then
sorted into one of 44 medication categories
(Scannell et al. 2013). Participants who
reported taking antihypertensive medication
were identified for the present study.
Lifestyle characteristics. Lifestyle charac
teristics were measured at baseline and followups, or only at baseline. Past or current use
of cigarette smoking was ascertained in the
questionnaire at each follow-up. Diabetes
status was identified by asking participants
if they were diagnosed with diabetes by a
physician. Previously reported comparisons
between self-reported diabetes status in our
study and test results for glycosylated hemoglobin and glucosuria showed that only 1% of
the individuals without self-reported diabetes
tested positive on urinary glucose, whereas
61% of the individuals with self-reported
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diabetes tested positive (p < 0.01), which indicated good questionnaire validity (Chen Y
et al. 2010, 2011). Body mass index (BMI)
was calculated based on measured height
and weight (kilograms per meter squared).
Educational status was obtained at baseline at
each follow-up.
Statistical analysis. We first conducted
descriptive analyses to compare the distribution
of demographic and lifestyle characteristics and
BP measurements over time by baseline water
arsenic categorized into quartiles in the overall
study population.
We used longitudinal mixed-effect models
with a random slope and an intercept for
each subject, to assess the association between
baseline arsenic, using either water or urinary
creatinine-adjusted arsenic, and annual
change in BP over time. The constructed
mixed-effects model is a two-level model, in
which the first level describes how BP changes
in the population (fixed effect), while the
second level of the model depicts how individual BP changes over time (random effect).
The mixed-effect model also accounts for
within-subject correlation between baseline
and follow-up BP measurements.
We first used the mixed-effect model to
assess the association of baseline demographic
and lifestyle variables with annual BP change.
The variables included baseline age (treated
as continuous or tertile variables), sex (male,
female), smoking status (never, past, current),
history of diabetes (yes, no), baseline educational attainment in years (continuous or
tertile variables), and BMI (kg/m2).
In order to investigate whether there was
a dose–response relationship between longterm exposure to arsenic (either baseline
water arsenic or baseline urinary creatinineadjusted arsenic) and longitudinal BP change,
arsenic concentrations were categorized into
quartiles, and the mixed-effect model was also
conducted as follows:
BPij = [β0 + β1 (TIME)ij + β2 As0j2
+ β3 As0j3 + β4 As0j4
+ β12 As0j2 (TIME)ij
+ β13 As0j3 (TIME)ij
+ β14 As0j4 (TIME)ij + αTZ0j]
+ [μ0j + μ1j (TIME)ij] + rij,

[1]

where baseline arsenic exposure (either water
arsenic or urinary creatinine-adjusted arsenic)
was categorized into quartiles and treated
with a dummy variable (As0j2, As0j3, As0j4).
BPij represents blood pressure at time i for
subject j. TIME is years since baseline at the
time of BP measurement; βk, k = 2,3,4 is the
difference in mean baseline BP for baseline
arsenic in the kth quartile compared with that
in the first quartile (reference); β1k, k = 2,3,4
is the difference in annual BP change over
time for baseline arsenic in the kth quartile

808

compared with the reference (i.e., the estimated effect of baseline arsenic levels on
annual BP change); α T is a row vector of
regression coefficient estimates for covariates
at baseline (T denotes vector transpose); and
Z0j is a vector of potential confounders. The
random intercept μ0j and slope μ1j estimate
the within-subject correlation among repeated
measurements and between-subject heterogeneity, and rij is the error that cannot be
accounted for by other covariates and random
effects. The terms in the first and second
brackets, respectively, are the fixed and
random parts of the model. An unstructured
variance structure was specified that assumes
that there was no specific pattern in the covariance matrix. BP was normally distributed
at baseline and follow-ups, and was therefore
not transformed. To assess the association
between baseline water arsenic and annual
BP change, we first adjusted for sex and age
(years) (model 1). We then additionally
adjusted for BMI (time dependent), smoking
status (time dependent, categorized into
current or not current), history of diabetes
(time dependent), and educational attainment
(model 2) because these variables were considered important risk factors for high BP in our
population (Chen Y et al. 2007a). Because
arsenic exposures may have changed from
baseline levels in some participants, in the
final model (model 3) we further adjusted for
change in urinary creatinine-adjusted arsenic
since baseline for each visit, calculated as the
arsenic concentration at each follow-up minus
arsenic concentration in the baseline. Similar
models were constructed using baseline
urinary creatinine-adjusted arsenic as the
exposure variable. We also examined differences in rate of BP change associated with
visit-to-visit changes in urinary creatinineadjusted arsenic.
In all analyses, BP measurements were
treated as missing for the visit when the use
of antihypertension treatment was reported
and thereafter. There were 126 participants
being treated with antihypertension medication at baseline, 285 at the first follow-up,
412 at the second follow-up, and 658 at
the third follow-up. We also conducted the
same analyses using different categories of
arsenic exposure (tertiles or quintiles). We
conducted sensitivity analyses excluding all
subjects who were ever under treatment at
baseline or at any follow-up visits. We used
the same equipment and protocol to measure
BP at baseline and at every follow-up visit.
However, because BP measurements in the
second follow-up appeared to be elevated
compared with BP measurements at other
time points, we did a sensitivity analysis to
exclude BP measurements in that follow-up.
Finally, we examined whether subjects
with higher baseline arsenic exposure (water
volume

arsenic or urinary creatinine-adjusted arsenic)
had higher BP at the end of follow-up. Linear
regression models were used, with the arsenic
exposure variables treated as categorical
variables, adjusting for the same covariates.
Adjusted mean levels of BP by quartiles of
arsenic exposure variables were estimated
using LSMEANS statement in SAS. All
statistical analyses were conducted using SAS,
version 9.3 (SAS Institute Inc., Cary, NC,
USA). All tests conducted were two-sided,
and p < 0.05 was considered significant.

Results
The final study population included 10,853
participants, with median follow-up time of
6.7 years, ranging from 0.86 to 8.26 years.
The median concentration was 62 μg/L
for water arsenic and 88 μg/L for urinary
arsenic, ranging from 0.1 to 864 μg/L and
1 to 2,273 μg/L, respectively. Of the study
population, 9,070 had all four SBP measurements and 9,062 had all four DBP measurements; 1,150 had three SBP measurements
and 1,159 had three DBP measurements; and
633 had two SBP measurements and 632 had
two DBP measurements. There were 10,853
subjects with available water arsenic concentrations and 10,549 subjects with available
baseline urinary creatinine-adjusted arsenic
concentrations for analysis.
Individuals with lower baseline arsenic
exposure were slightly more likely to have
higher educational attainment or higher
baseline BMI (Table 1). There was no
significant difference in SBP or DBP by
water arsenic tertile groups at baseline, first
follow-up, or second follow-up. However,
there were global differences in SBP and
DBP measured at the third visit in relation
to baseline water arsenic levels. Baseline water
arsenic levels were positively associated with
urinary creatinine-adjusted arsenic levels at
baseline, first follow-up, second follow-up,
and third follow-up.
The rate of annual SBP increase tended
to be greater with increasing baseline age
(Table 2). Age was inversely associated with
the rate of longitudinal DBP increase. There
was a monotonic decrease with increasing
age, comparing older age groups (30–40,
> 40 years of age) with younger age group
(≤ 30 years of age), and the difference
between the rate of DBP decrease among
those > 40 years at baseline was close to
being significantly lower than the rate among
those ≤ 30 years at baseline. The data are
consistent with previous literature that documented a decreasing DBP with increasing
age (Wright et al. 2011). The annual increase
in SBP was greater in women compared
with men, in those with higher educational
attainment than subjects with a lower
educational attainment, and in those with a
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baseline BMI > 20.45 kg/m2 compared with
18.09–20.45 kg/m2.
Tables 3 and 4 show the associations
of arsenic exposure categorized into quartiles and annual change in SBP or DBP.
For SBP, we observed a positive association without a dose–response relationship
throughout three models; individuals in
the higher three quartiles of baseline water
arsenic or urinary creatinine-adjusted
arsenic had a greater annual increase in
SBP compared with those in the reference group (β = 0.43–0.54 mmHg/year
and β = 0.39–0.44 mmHg/year for water
arsenic and urinary creatinine-adjusted
arsenic, respectively) in fully adjusted models
(Table 3). Likewise, for DBP, a positive relationship was also observed; individuals in
the higher three quartiles of baseline arsenic
exposure had a greater annual increase in
DBP (β = 0.39–0.41 mmHg/year, and
β = 0.37–0.45 mmHg/year for water arsenic
and urinary creatinine-adjusted arsenic,
respectively) in fully adjusted models
compared with those in the lowest quartile
(Table 4). For DBP there was a monotonic
increase in the rate with increasing urinary
creatinine-adjusted arsenic (Table 4). Analyses
using different categories of arsenic exposure
(tertiles or quintiles) showed similar results
(see Supplemental Material, Tables S2
and S3). Sensitivity analyses were conducted
by excluding all subjects who were under
treatment for hypertension at baseline or

creatinine) had a positive but nonsignificant
association with the mean annual increase in
SBP [β = 0.40; 95% confidence interval (CI):
–0.04, 0.83] and DBP (β = 0.28; 95% CI:
–0.03, 0.59), whereas there was no association with a decrease of > 9 μg/g creatinine
over follow-up (data not shown). Because
mean SBP and DBP both were highest at the
second follow-up visit (suggesting a possible
systematic error in measurement), we repeated

follow-up (n = 545), without change in the
overall results (data not shown). In an analysis
of associations with changes in creatinineadjusted urinary arsenic over time, with
the least amount of change between visits
(creatinine-adjusted urinary arsenic at later
visit minus creatinine-adjusted urinary arsenic
at earlier visit) as the reference group (ranging
from a decrease of 9 to an increase of 39 μg/g
creatinine), the greatest increase (> 39 μg/g

Table 2. Relation of baseline characteristics and adjusted annual changes in blood pressure over 7 years
of follow-up.a
Baseline characteristic
Age (years)b
≤ 30
30–40
> 40
Sex (women compared with
men)
Smoking statusb
Never
Past
Current
Diabetes history
Education length (years)b
0
0–5
>5
BMI baseline (kg/m2)b
≤ 18.09
18.09–20.45
> 20.45

SBP change/year (mmHg)
β (95% CI)

p-Value

DBP change/year (mmHg)
β (95% CI)

p-Value

Reference
0.14 (0.02, 0.27)
0.36 (0.23, 0.49)
0.34 (0.20, 0.48)

0.020
< 0.001
< 0.001

Reference
–0.05 (–0.14, 0.03)
–0.09 (–0.18, 0.01)
0.01 (–0.10, 0.10)

0.201
0.064
0.950

Reference
–0.01 (–0.23, 0.22)
0.11 (–0.05, 0.26)
–0.19 (–0.53, 0.14)

0.939
0.179
0.257

Reference
–0.05 (–0.21, 0.10)
0.08 (–0.03, 0.19)
–0.22 (–0.46, 0.01)

0.529
0.168
0.060

Reference
0.18 (0.06, 0.29)
0.28 (0.16, 0.41)

0.003
< 0.001

Reference
0.06 (–0.02, 0.14)
0.02 (–0.07, 0.10)

0.135
0.669

–0.03 (–0.15, 0.10)
Reference
0.19 (0.06, 0.31)

0.660

0.07 (–0.01, 0.16)
Reference
–0.07 (–0.16, 0.01)

0.003

0.089
0.09

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index.
aWhen one variable was put in the model, all other variables were adjusted in the same model. bCategorized by tertiles.

Table 1. Baseline and follow-up characteristics of HEALS participants (N = 10,853).
Q1 (≤ 12 μg/L)
No.
Mean ± SD or %
Characteristic
Age (years)
2,752
36.9 ± 10.0
Male (%)
1,170
42.5
Current smoker (%)
813
29.6
Diabetes history (%)
55
2.0
Education (years)
2,750
3.6 ± 3.9
BMI baseline (kg/m2)
2,730
19.9 ± 3.3
Systolic blood pressure (mmHg)
Baseline
2,752
113.6 ± 16.6
Follow up 1
2,676
113.9 ± 16.8
Follow up 2
2,557
118.4 ± 15.6
Follow up 3
2,432
108.5 ± 14.9
Diastolic blood pressure (mmHg)
Baseline
2,750
73.8 ± 11.5
Follow up 1
2,677
73.0 ± 10.2
Follow up 2
2,557
76.3 ± 10.3
Follow up 3
2,432
71.1 ± 9.9
Urinary arsenic (μg/L)
Baseline
2,711
51.0 ± 47.7
Follow up 1
2,671
54.3 ± 57.7
Follow up 2
2,621
54.7 ± 55.6
Follow up 3
2,564
51.6 ± 57.5
Urinary creatinine-adjusted arsenic (μg/g creatinine)
Baseline
2,711
99.8 ± 83.5
Follow up 1
2,671
96.7 ± 74.4
Follow up 2
2,621
98.5 ± 79.4
Follow up 3
2,564
99.0 ± 89.5

Q2 (12–62 μg/L)

Q3 (62–148 μg/L)

Q4 (> 148 μg/L)
Mean ± SD or %
37.0 ± 10.0
42.6
27.8
1.6
3.3 ± 3.7
19.4 ± 3.0

p-Valuea
0.234
0.935
0.334
0.370
0.002
< 0.001

No.
2,711
1,143
792
59
2,710
2,701

Mean ± SD or %
36.6 ± 10.0
42.2
29.2
2.2
3.2 ± 3.7
19.7 ± 3.1

No.
2,688
1,124
747
46
2,687
2,670

Mean ± SD or %
36.6 ± 9.9
41.8
27.8
1.7
3.5 ± 3.9
19.7 ± 3.0

No.
2,702
1,151
751
43
2,700
2,690

2,711
2,639
2,475
2,399

114.7 ± 17.2
113.7 ± 17.0
117.8 ± 15.3
112.6 ± 14.8

2,688
2,623
2,492
2,366

113.6 ± 16.5
113.5 ± 17.1
117.8 ± 15.5
112.6 ± 15.7

2,702
2,639
2,489
2,356

113.5 ± 16.6
114.2 ± 17.4
117.4 ± 15.2
112.0 ± 15.6

0.391
0.442
0.175
< 0.001

2,711
2,638
2,475
2,399

73.6 ± 11.3
72.8 ± 10.3
76.2 ± 10.0
73.9 ± 10.0

2,685
2,623
2,492
2,366

73.4 ± 11.1
72.6 ± 10.2
76.1 ± 10.0
73.8 ± 10.2

2,700
2,639
2,489
2,356

73.1 ± 11.5
72.9 ± 10.3
76.0 ± 10.1
73.4 ± 10.1

0.132
0.557
0.683
< 0.001

2,662
2,633
2,534
2,510

99.2 ± 79.3
106.9 ± 87.5
105.7 ± 85.5
92.8 ± 77.7

2,576
2,625
2,547
2,499

150.9 ± 120.4
145.3 ± 133.8
139.1 ± 125.6
118.6 ± 108.8

2,600
2,629
2,542
2,484

258.2 ± 233.8
185.7 ± 199.1
178.5 ± 191.4
149.2 ± 169.5

< 0.001
< 0.001
< 0.001
< 0.001

2,662
2,633
2,534
2,510

209.1 ± 151.7
193.1 ± 121.8
198.0 ± 120.6
190.2 ± 153.6

2,576
2,625
2,547
2,499

316.8 ± 200.5
264.2 ± 213.6
259.2 ± 201.1
247.8 ± 191.2

2,600
2,629
2,542
2,484

525.8 ± 488.1
344.9 ± 326.7
333.1 ± 323.1
305.1 ± 309.7

< 0.001
< 0.001
< 0.001
< 0.001

Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4. Q1: median = 2.3, SD = 3.3, range = 11.9; Q2: median = 34.0, SD = 14.4, range = 49.7; Q3: median = 101.0, SD = 25.2,
range = 86.0; Q4: median = 239.0, SD = 107.4, range = 714.0.
aRepresents the global difference and is based on the chi-square test for categorical variables and analysis of variance for continuous variables.
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analyses excluding follow-up 2 data but found
similar results to analyses including data from
all visits (data not shown).
Last, we assessed the association between
baseline arsenic exposure and the absolute
levels of BP at the third follow-up (see
Supplemental Material, Figure S1). In fully
adjusted models, individuals with the highest
level of baseline water arsenic had 3.95 mmHg
(95% CI: 3.15, 4.76) greater SBP or 2.65
mmHg (95% CI: 2.21, 3.31) greater DBP
compared with those in the reference group.
Similarly, for urinary creatinine-adjusted
arsenic, individuals with higher concentrations had a 3.47 mmHg (95% CI: 2.61, 4.33)
increase in SBP or a 2.62 mmHg (95% CI:
1.95, 3.03) increase in DBP compared with
those in the lowest quartile. However, associations were similar across quartiles 2, 3, and 4,
without evidence of a monotonic trend (see
Supplemental Material, Figure S1).

Discussion
To our knowledge, the present study is the
first large epidemiologic study to examine
the relationship between arsenic exposure
from drinking water and longitudinal change
in BP. We found positive associations of
arsenic exposure, measured either in well
water or urine samples, with annual change
in SBP and DBP, over an average of 6.7 years
of follow-up.
The association of arsenic exposure
with BP has been indicated in several crosssectional studies. A systematic review including
11 cross-sectional studies reported a pooled
OR of 1.27 (95% CI: 1.09, 1.47; p-value for
heterogeneity = 0.001) for high BP comparing
the highest and lowest arsenic exposure
categories (Abhyankar et al. 2012). However,
cross-sectional assessments of the association
between arsenic exposure and BP are limited
by a) possible selection bias in capturing only
individuals who have lived long enough, and
b) limited detection of the latent effects of
arsenic exposure on BP. In contrast, longitudinal analyses mitigate some of these problems
and may be a superior method for examining
arsenic exposure on BP change over time.
Longitudinal analyses have previously revealed
the effects of lead exposure on BP change
(Glenn et al. 2003, 2006). Our findings
demonstrating an association between arsenic
exposure and annual BP change contributes to
the growing body of evidence indicating that
environmental exposures may play a role in
longitudinal BP change.
We did not find a monotonic relationship between arsenic exposure and the slope
of BP change over time. In our previous
cross-sectional study, the positive association between arsenic exposure from drinking
water and baseline BP also was not stronger
with increasing quartiles of arsenic exposure
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(Chen Y et al. 2007a). Mechanistic studies
have indicated that the vascular effect of arsenic
may be nonlinear (Soucy et al. 2003) and may
reach threshold when arsenic exposure exceeds
a certain level. Alternatively, the baseline BP
may have been affected by arsenic exposure
already leading to a limited increase on the rate
of BP change that can be further observed. In
addition, the increased rate of BP change may
be limited in this relatively young cohort.
In the present study, exposure to water
with arsenic concentrations > 12 μg/L was
associated with a greater increase of 0.43–
0.54 mmHg/year and 0.39–0.41 mmHg/year
for SBP and DBP, respectively. Evidence
suggests that the risk of CVD rises continuously as both SBP and DBP increase from
115 mmHg and 75 mmHg, respectively
(Lewington et al. 2002). Based on estimates
from 61 prospective observational studies,
even a 2‑mmHg decrease in usual SBP would
involve about 10% lower stroke mortality
and about 7% lower mortality from ischemic
heart disease or other vascular causes in
middle age (Lewington et al. 2002). Although
the estimate may not be the same in our
study population, given the strong association
between BP and CVD risk, the differences in
the rate of BP change associated with arsenic

exposure, although small in magnitude
annually, may have a cumulative effect on the
risk of clinical events.
The potential association between arsenic
exposure and high BP is supported by experimental studies. In vitro work has shown that
arsenic promotes inflammatory activity, oxidative stress, and endothelial dysfunction through
several mechanisms, including the activation
of stress-response transcription factors such
as activator protein‑1 and nuclear factor‑κB
(Abhyankar et al. 2012). In animal models,
chronic exposure of rats and rabbits to arsenite
has been shown to cause a considerable
increase in peripheral vascular resistance (Abir
et al. 2012). In rats, lifelong arsenic exposure
increased BP after only 80 days, and elevations persisted through 200 days (Yang et al.
2007). Furthermore, arsenic exposure may also
be related to renal dysfunction, leading to BP
changes in individuals (Chen JW et al. 2011;
Hsueh et al. 2009).
Our study, which is among the first to
prospectively investigate the role of arsenic
exposure in longitudinal BP change, has
several strengths. First, we have obtained
multiple research-quality BP measurements
over 7 years of follow-up, which enables us
to depict BP longitudinal change over time.

Table 3. Relation of baseline water arsenic (N = 10,853) and baseline urinary creatinine-adjusted arsenic
(N = 10,549) with adjusted annual changes in systolic blood pressure (SBP) over 7 years of follow-up.
Baseline exposure
Water arsenic (μg/L)
Q1
Q2
Q3
Q4
Urinary creatinine-adjusted arsenic
(μg/g creatinine)
Q1
Q2
Q3
Q4

Range

Model 1
Model 2
Model 3
change/year (mmHg) change/year (mmHg) change/year (mmHg)

< 12
12–62
62–148
> 148

Reference
0.45 (0.32, 0.58)
0.60 (0.46, 0.73)
0.51 (0.38, 0.65)

Reference
0.42 (0.29, 0.56)
0.55 (0.42, 0.68)
0.48 (0.34, 0.61)

Reference
0.43 (0.29, 0.56)
0.54 (0.40, 0.67)
0.48 (0.35, 0.61)

< 106
106–199
199–352
> 352

Reference
0.40 (0.26, 0.53)
0.45 (0.32, 0.59)
0.45 (0.31, 0.58)

Reference
0.38 (0.25, 0.52)
0.43 (0.30, 0.57)
0.41 (0.27, 0.54)

Reference
0.39 (0.25, 0.52)
0.44 (0.30, 0.58)
0.43 (0.29, 0.56)

Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4. Model 1: controlled for baseline age and
sex. Model 2: controlled for model 1 covariates plus BMI, smoking status, educational status, and history of diabetes.
Model 3: controlled for model 2 covariates plus change of urinary creatinine-adjusted arsenic since baseline.

Table 4. Relation of baseline water arsenic (N = 10,846), baseline urinary creatinine-adjusted arsenic
(N = 10,549) with adjusted annual changes in diastolic blood pressure (DBP) over 7 years of follow-up.
Model 1
Model 2
Model 3
Baseline exposure
Range change/year (mmHg) change/year (mmHg) change/year (mmHg)
Water arsenic (μg/L)
Q1
< 12
Reference
Reference
Reference
Q2
12–62
0.44 (0.35, 0.53)
0.42 (0.33, 0.52)
0.41 (0.31, 0.50)
Q3
62–148
0.47 (0.38, 0.56)
0.42 (0.33, 0.52)
0.41 (0.32, 0.51)
Q4
> 148
0.43 (0.34, 0.52)
0.40 (0.31, 0.49)
0.39 (0.30, 0.49)
Urinary creatinine-adjusted arsenic
(μg/g creatinine)
Q1
< 106
Reference
Reference
Reference
Q2
106–199
0.38 (0.29, 0.48)
0.37 (0.27, 0.46)
0.37 (0.27, 0.46)
Q3
199–352
0.40 (0.30, 0.49)
0.37 (0.27, 0.46)
0.38 (0.28, 0.47)
Q4
> 352
0.49 (0.40, 0.58)
0.45 (0.35, 0.54)
0.45 (0.36, 0.55)
Abbreviations: Q1, quartile 1; Q2, quartile 2; Q3, quartile 3; Q4, quartile 4. Model 1: controlled for baseline age and
sex. Model 2: controlled for model 1 covariates plus BMI, smoking status, educational status, and history of diabetes.
Model 3: controlled for model 2 covariates plus change of urinary creatinine-adjusted arsenic since baseline.
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Second, the low percentage of the population
using antihypertensive medications (around
1% at baseline) and the absence of alcohol
consumption due to religious beliefs allowed
us to investigate BP change without the influence of medical therapy or alcohol. Finally,
we have a rich set of covariates that allow us
to adjust for confounders.
The study also has limitations. Although
we used the same methodology for measuring
BP since baseline and for follow-ups,
measurement errors for BP measurements
could have occurred. We could not estimate
the extent of the potential measurement
errors. However, the relationships between
conventional risk factors and longitudinal
change in BP were consistent with those of
the literature, supporting the validity of the
BP measurement in this study. Also, sensitivity analysis excluding follow-up 2, which
was conducted out of concern for error at
follow-up 2, generated similar results. The selfreported well water use might also produce
misclassifications of exposure. However, the
correlation of well water arsenic concentration and urinary creatinine-adjusted arsenic
at baseline was high (ρ = 0.70), supporting
the validity of self-reported data on well use
and population-wide arsenic exposure in this
population. The analyses were restricted to
individuals with available data on repeated
BP measurements. Because arsenic exposure
has been related to CVD mortality in the
cohort and high BP is a CVD risk factor,
the exclusion of individuals without repeated
BP measurements may have preferentially
removed individuals with high BP that is
associated with arsenic, leading to a potential
bias toward the null on average. However,
missing BP was not extensive (9,069 subjects
have complete BP measurements), and the
demographic distributions of our study population and the overall population were very
similar (see Supplemental Material, Table S1).
In the analyses, we controlled for visit-to-visit
changes in urinary creatinine-adjusted arsenic.
However, given that arsenic exposure was
similar in the majority of participants, we may
not have power to assess the effects of changes
in urinary creatinine-adjusted arsenic. We
did not assess the role of specific nutrients or
nutritional intake in the present study. Future
studies are needed to investigate whether the
association of arsenic exposure and the rate of
BP change differs by nutritional status.

Conclusion
We found positive associations between
long-term arsenic exposure and BP increase
over time, which might be one mechanism
by which arsenic may lead to CVD. Further
studies are needed to investigate other
preclinical indicators or biomarkers of CVD
with multiple measurements.
Environmental Health Perspectives •
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